NCT06613841 (GBM) is a EARLY_PHASE1 clinical trial of Fluciclovine F18 in Glioblastoma, sponsored by Abramson Cancer Center at Penn Medicine.

Who is sponsoring NCT06613841?

NCT06613841 is sponsored by Abramson Cancer Center at Penn Medicine.

What drugs are being tested in NCT06613841?

Interventions in NCT06613841: Fluciclovine F18.

What condition does NCT06613841 study?

NCT06613841 studies Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain.

Is NCT06613841 still recruiting?

NCT06613841 is currently recruiting now. Last updated 28 November 2025.

Last reviewed 2025-11-28 · How we verify

NCT06613841: GBM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Recruiting now EARLY_PHASE1 Last updated 28 November 2025

What this trial tests

EARLY_PHASE1 trial testing Fluciclovine F18 in Glioblastoma in 15 participants. Currently enrolling.

Timeline

1 May 2025

Primary endpoint
1 October 2026

31 December 2026

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	15
Start date	1 May 2025
Primary completion	1 October 2026
Estimated completion	31 December 2026
Sites	2 locations across United States

Drugs / interventions tested

Fluciclovine F18 — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
Glioblastoma Multiforme of Brain — all drugs for Glioblastoma Multiforme of Brain →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Glioblastoma or Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.
Ribeiro A, Fote G, Himstead A, Zheng M, et al · · 2025 · cited 3× · PMID 40868217 · DOI 10.3390/biomedicines13081963

Verify or expand the search:

Other trials of Fluciclovine F18

Trials testing the same drug.

NCT06064097 — A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) · Phase 2 · recruiting
NCT06319027 — Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Tr · Phase 2 · recruiting
NCT05053152 — Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Pr · Phase 2 · active not recruiting
NCT04750473 — Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer · Phase 1 · completed
NCT04423211 — Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging · Phase 3 · recruiting

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06613841 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 28 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06613841.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing